| Chen, Minshan |
NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 06/24 | 12/24 | | |
NCT04652440: Ablation Combined With PD-1 in HCC: Phase II Study |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 monoclonal antibody, Tislelizumab, Radiofequencey or microwave ablation, ablation | Sun Yat-sen University | Hepatocellular Carcinoma | 12/23 | 06/24 | | |
NCT04454905: Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study |
|
|
| Recruiting | 2 | 50 | RoW | Camrelizumab, Camrelizumab for Injection, Apatinib, Rivoceranib | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Intrahepatic Cholangiocarcinoma | 07/24 | 07/25 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Recruiting | N/A | 456 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
| Ratti, Véronique Loustaud |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
|
|
| Active, not recruiting | 2 | 42 | Europe, US | IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2 | 03/24 | 12/24 | | |
| Zhang, Ping |
NCT04683406: A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A |
|
|
| Completed | 3 | 750 | RoW | ZSP1273 600 mg, Placebo to Oseltamivir, Oseltamivir(oral), Placebo to ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Influenza A | 04/23 | 05/23 | | |
NCT04479553: Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study. |
|
|
| Recruiting | N/A | 30000 | RoW | Qizhi Tongluo Capsules | Zhong Wang, Shanxi Zhendong Pharmacy Co., Ltd | Safety Surveillance, Adverse Drug Events, Adverse Drug Reactions, Severe Adverse Events, Severe Adverse Reactions | 09/23 | 12/23 | | |
| Recruiting | N/A | 4009 | RoW | CYP2C19 genotype testing, clopidogrel, ticagrelor | Beijing Anzhen Hospital | Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype | 12/24 | 02/25 | | |
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus |
|
|
| Recruiting | N/A | 184 | RoW | Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter | Shanghai Bluesail Boyuan Medical Technology Co., Ltd. | Coronary Artery Disease, Intravascular Lithotripsy | 12/24 | 09/25 | | |
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study |
|
|
| Recruiting | N/A | 2500 | RoW | | AstraZeneca | NASH With Fibrosis | 12/26 | 12/26 | | |
NCT03261934: Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation |
|
|
| Recruiting | N/A | 2000 | RoW | No intervention | Beijing University of Chinese Medicine, The University of Science and Technology of China, China Academy of Chinese Medical Sciences, Harvard Medical School (HMS and HSDM) | Risk Assessment of Chronic Atrophic Gastritis Malignant Transformation | 12/30 | 12/30 | | |
| Zheng, Ling |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05345964: Phase I Study of GST-HG151 Tablets in Healthy Volunteers |
|
|
| Recruiting | 1 | 112 | RoW | GST-HG151, Placebo | Fujian Cosunter Pharmaceutical Co. Ltd | Healthy Volunteers | 03/23 | 05/23 | | |
| Lin, Minghua |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
| Huang, Zuxiong |
NCT05734807: A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia |
|
|
| Active, not recruiting | 2a | 75 | RoW | Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs), HH-003 and NrtIs, HH-003, NrtIs and PEG-IFN-α | Huahui Health | Chronic HBV Infection | 04/23 | 03/24 | | |
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B |
|
|
| Not yet recruiting | 1/2 | 162 | RoW | TQA3038 injection/placebo, Nucleotide drugs Control group | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B, Chronic | 09/26 | 09/26 | | |
NCT04564651: Platelet Transfusion in Acute-on Chronic Liver Failure |
|
|
| Recruiting | N/A | 80 | RoW | platelet transfusion | Nanfang Hospital of Southern Medical University | Acute-On-Chronic Liver Failure | 05/24 | 05/24 | | |
| Zeng, Yongyi |
NCT06349317: Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT |
|
|
| Not yet recruiting | 2 | 33 | NA | Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib | Yongyi Zeng | Hepatocellular Carcinoma | 05/26 | 06/26 | | |
NCT05140837: Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106) |
|
|
| Recruiting | N/A | 10000 | RoW | Psychometric hepatic encephalopathy score & Stroop test, Drug therapy | Hepatopancreatobiliary Surgery Institute of Gansu Province, The First Affiliated Hospital of Anhui Medical University, Beijing Ditan Hospital, Chongqing Public Health Medical Treatment Center, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Guangxi Zhuang Autonomous Region People's Hospital, Shenzhen Third People's Hospital, Guizhou people's Hospital, Wuhan Union Hospital, China, Xiangya Hospital of Central South University, The Second Affiliated Hospital of Hainan Medical University, The Third Affiliated Hospital of Hebei Medical University, The Second Affiliated Hospital of Harbin Medical University, Henan Provincial People's Hospital, Ganzhou Fifth People's Hospital, The First Hospital of Jilin University, Jiangsu People's Hospital, First Hospital of China Medical University, The Second Affiliated Hospital of Baotou Medical College, Ningxia Medical University General Hospital, The Fourth People's Hospital of Qinghai Province, Xi'an High-tech Hospital, The 10th People's Hospital affiliated to Tongji University, Qilu Hospital of Shandong University, The Third People's Hospital of Taiyuan, Xichang People's Hospital, Tianjin Third Central Hospital, The Third People's Hospital of Tibet Autonomous Region, Xinjiang Autonomous Region People's Hospital, Second People's Hospital of Yunnan Province, Hangzhou Xixi hospital, LanZhou University | Hepatic Encephalopathy, Cirrhosis | 12/24 | 12/24 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Recruiting | N/A | 456 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
| Chen, Yanling |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
| Lin, Kecan |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
